Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03140631 · ClinicalTrials.gov registry record · Phase 4
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
NCT03140631 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 153 participants.
The verdict
NCT03140631, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, efficacy and efficiency of rapid anticoagulation reversal with protamine sulfate versus routine activated clotting time (ACT) monitoring in patients undergoing catheter based ablation of atrial fibrillation.
Interventions
- DRUG Protamine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2017-03-23 |
| Est. Completion | 2018-04-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03140631
The ClinicalTrials.gov registry entry for NCT03140631 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Protamine Sulfate is the first listed.
NCT03140631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03140631 about?
NCT03140631 is a clinical study titled "Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation". The objective of this study is to evaluate the safety, efficacy and efficiency of rapid anticoagulation reversal with protamine sulfate versus routine activated clotting time (ACT) monitoring in patients undergoing catheter based ablation of atrial fibrillation.
What is the current status of trial NCT03140631?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 2017-03-23. Estimated completion is 2018-04-03.
What interventions are being tested in trial NCT03140631?
The interventions under investigation include: Protamine Sulfate (DRUG).
Who is sponsoring clinical trial NCT03140631?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.